Explainer4 min read
AbbVie did not cut its guidance. Its guidance was never whole
The company lowered its earnings range by eleven cents because it spent $216 million on deals. It will happen again next quarter, by design, and the design deserves more scrutiny than the eleven cents.
On Monday AbbVie filed a short document with the SEC. It said the third quarter will include $216 million of "acquired IPR&D and milestones expense", that this takes $0.11 off earnings per share, and that the company's guidance for 2026 adjusted earnings moves from a range of $13.87 to $14.07 a share down to $13.76 to $13.96. The quarter's own range moves from $3.84 to $3.88 down to $3.73 to $3.77.
Our news desk tagged it bearish. Taken literally, that is right: a company told investors to expect less profit than it had told them before. But I think the literal reading misses what happened, and the better question is why this filing exists at all.
The eleven cents are the whole story
Notice what did not change. Both ends of the annual range fell by exactly eleven cents. Both ends of the quarterly range fell by exactly eleven cents. The charge is worth eleven cents.
Nothing else moved. The filing says nothing about sales, about any product, about demand, about costs. The company did not learn something bad about its business and pass it on. It spent money on deals and subtracted that money from a forecast that, until then, had assumed it would spend none.
That last part is the point. The filing says so in plain words: AbbVie "does not forecast acquired IPR&D and milestones expense" because it cannot know when such transactions will happen, and its guidance excludes any such expense "that may be incurred beyond the third quarter".
A forecast that leaves out a cost it knows it will have
Acquired in-process research and development is what a drug company pays when it buys or licenses an experimental medicine that is not yet approved. Milestones are the further payments owed when that medicine clears a hurdle. For a company whose future products come partly from outside its own laboratories, these are not accidents. They are how the pipeline is filled.
The filing's own table shows how regular they are. Before the third quarter, AbbVie's guidance for the year already included $1,035 million of this expense. With the third quarter it is $1,251 million. That is a billion and a quarter dollars in nine months of a cost the annual forecast treats, at the start of each quarter, as zero for the rest of the year.
So the sequence repeats. The company guides. A quarter passes in which it does deals, as it always does. It files a notice lowering guidance by the cost of those deals. Headlines say guidance was cut. Then the next quarter begins and the forecast again assumes no deals.
Two wrong ways to read it
The first wrong reading is alarm. A reader who sees "AbbVie lowers guidance" and concludes the business is deteriorating has been misled by a convention. The filing contains no evidence of that at all.
The second wrong reading is the opposite, and I think it is the more common one: to wave the charge away as a one-off that does not count. It is in adjusted earnings precisely because it does count. The company itself includes it in the adjusted figure rather than stripping it out, and the cash is real. A cost that reaches $1,251 million by September is not a footnote.
The honest reading sits between the two. The guidance given at the start of a quarter is a forecast before deals, and the true expectation is that figure less whatever the company ends up spending, which experience says is not nothing.
What I would change
The company's reason for not forecasting the expense is reasonable on its face. Deals are lumpy and their timing is unknowable. A forecast of them would often be wrong.
But a forecast that is known to be too high is also wrong, and it is wrong in the same direction every time. I would rather see a range for the year's expected spending on acquired research, stated as an assumption, with guidance given both before and after it. Other costs that are hard to time are forecast as ranges. This one could be.
Until then, the filing on Monday is best read as bookkeeping. What would make it something more is a quarter in which the range moves by a different amount than the charge. That would be news about the business. This was not.
Comments